New Gene Therapies for Sickle Cell Anemia to be Considered by FDA

Follow Drugslib on

By Physician’s Briefing Staff HealthDay Reporter

MONDAY, Oct. 30, 2023 -- Patients with sickle cell disease may soon have two new treatments to try. On Tuesday, a U.S. Food and Drug Administration advisory committee will weigh the merits of a new gene therapy for the painful, inherited condition. The agency is expected to make a decision on that therapy in early December, and it also plans to decide on a second new treatment before year's end, the Associated Press reported.

The treatment being reviewed Tuesday is based on CRISPR technology, a gene-editing tool. The inventors of that tool won the Nobel Prize in 2020 for their work, the AP reported. A one-time treatment, "exa-cel" is made by Vertex Pharmaceuticals and CRISPR Therapeutics, and it permanently changes DNA in a patient's blood cells.

On Tuesday, FDA advisers will consider whether more research is needed into potential unintended consequences of the new gene therapy.

In briefing documents filed with the advisory committee, Vertex said that 46 people got the treatment in its study. Among the 30 who had 18 months of follow-up, 29 were free of pain crises for at least a year and all 30 avoided being hospitalized for pain crises. Still, the FDA advisory panel is asking outside gene therapy experts to discuss the possibility of "off-target effects" (i.e., unexpected changes to a person's genome). The FDA would like to determine whether company research on these possible effects has been adequate or whether more studies are needed, the AP reported. The company has proposed a postapproval safety study and product labeling that notes potential risks.

The second gene therapy for sickle cell disease that the FDA will consider is intended to work by making functional copies of a modified gene, the AP reported. This helps red blood cells produce hemoglobin that is not misshapen. That treatment is made by Bluebird Bio.

Prices for the two gene therapies have not been released, the AP reported. However, a price tag of around $2 million would be considered cost-effective because the existing treatments cost about $1.6 million for women and $1.7 million for men from birth to age 65 years, according to recent research.

Associated Press Article

Posted : 2023-10-31 13:55

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords